Patents by Inventor Minoru Ueda
Minoru Ueda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12072583Abstract: Provided is a dimming laminate which can effectively suppress occurrence of color unevenness and light omission. The dimming laminate according to the present invention includes a first transparent base material, a second transparent base material, and a dimming layer disposed between the first transparent base material and the second transparent base material. In this dimming laminate, the dimming layer includes a resin spacer, the resin spacer is a plurality of resin particles, and the resin spacer does not contain resin particles having a particle diameter of 1.4 times or more an average particle diameter of the resin particles or contains 0.0006% or less of the resin particles having a particle diameter of 1.4 times or more the average particle diameter of the resin particles, relative to 100% of the whole number of the resin particles.Type: GrantFiled: March 31, 2023Date of Patent: August 27, 2024Assignee: SEKISUI CHEMICAL CO., LTD.Inventors: Yasuyuki Yamada, Hideyuki Takahashi, Saori Ueda, Minoru Nakajima
-
Patent number: 11135243Abstract: The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.Type: GrantFiled: July 24, 2018Date of Patent: October 5, 2021Assignee: SHED Tech CorporationInventors: Minoru Ueda, Yoichi Yamada, Katsumi Ebisawa, Akihito Yamamoto, Kiyoshi Sakai, Kohki Matsubara, Hisashi Hattori, Masahiko Sugiyama, Takanori Inoue
-
Patent number: 11000572Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.Type: GrantFiled: November 1, 2019Date of Patent: May 11, 2021Assignee: TOKUSHIMA UNIVERSITYInventors: Akihito Yamamoto, Minoru Ueda, Kohki Matsubara, Akio Suzumura, Koichi Furukawa, Yoshihiro Matsushita, Hirotaka Wakayama, Nobunori Takahashi, Shin Tsunekawa, Takako Izumoto
-
Patent number: 10709741Abstract: A composition for preventing or treating inflammatory disease and that is effective for inflammatory disease such as fulminant hepatitis and interstitial pneumonia. For such an objective, the present uses a culture supernatant obtained by culturing dental pulp stem cells as the active ingredient of the composition for preventing or treating inflammatory disease.Type: GrantFiled: February 13, 2014Date of Patent: July 14, 2020Assignee: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITYInventors: Akihito Yamamoto, Minoru Ueda, Hidemi Goto, Masatoshi Ishigami, Yoshihiro Matsushita, Yoshinori Hasegawa, Naozumi Hashimoto, Hirotaka Wakayama
-
Patent number: 10639355Abstract: The invention provides a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27° C. under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.Type: GrantFiled: January 23, 2015Date of Patent: May 5, 2020Assignee: QUARRYMEN & Co. Inc.Inventor: Minoru Ueda
-
Publication number: 20200129591Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.Type: ApplicationFiled: November 1, 2019Publication date: April 30, 2020Applicant: TOKUSHIMA UNIVERSITYInventors: Akihito YAMAMOTO, Minoru UEDA, Kohki MATSUBARA, Akio SUZUMURA, Koichi FURUKAWA, Yoshihiro MATSUSHITA, Hirotaka WAKAYAMA, Nobunori TAKAHASHI, Shin TSUNEKAWA, Takako IZUMOTO
-
Patent number: 10507230Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.Type: GrantFiled: March 28, 2018Date of Patent: December 17, 2019Assignee: TOKUSHIMA UNIVERSITYInventors: Akihito Yamamoto, Minoru Ueda, Kohki Matsubara, Akio Suzumura, Koichi Furukawa, Yoshihiro Matsushita, Hirotaka Wakayama, Nobunori Takahashi, Shin Tsunekawa, Takako Izumoto
-
Patent number: 10494606Abstract: The purpose of the present invention is to provide immortalized stem cells, which produce a growth factor capable of regenerating various kinds of tissues that have been damaged by a variety of causes, and a method for producing the aforesaid immortalized stem cells. Another purpose is to provide a medicinal composition and a medicinal preparation for restoring damaged tissues, and a method for the percutaneous absorption of a culture supernatant. Provided are immortalized stem cells that are obtained by isolating stem cells selected from the group consisting of mammalian mesenchymal cells, an embryo at the early stage of the development and somatic cells, first culturing the cells to give first stage culture cells, transferring four kinds of genes into the first stage culture cells to give transgenic cells, and selecting the desired immortalized stem cells from among the transgenic cells using the expression of STRO-1 as an index.Type: GrantFiled: June 26, 2017Date of Patent: December 3, 2019Assignee: QUARRYMEN&Co. Inc.Inventor: Minoru Ueda
-
Patent number: 10139605Abstract: A zoom lens comprises in order from an object side, a first lens unit having a positive refractive power, a second lens unit having a negative refractive power, and a third lens unit having a positive refractive power, and the third unit having a positive refractive power comprises in order from the object side, a first lens component having a positive refractive power, and a second lens component having a negative refractive power in which, a lens having a positive refractive power and a lens having a negative refractive power are cemented, and the zoom lens satisfies the following conditional expressions (1), (2), and (3) 1.4<|f3_2p/f3_2n|<2.6??(1) nd3_2p?nd3_2n?0??(2) nd3_2n?1.8??(3).Type: GrantFiled: January 26, 2016Date of Patent: November 27, 2018Assignee: OLYMPUS CORPORATIONInventors: Tetsuya Yanai, Minoru Ueda, Mayu Miki
-
Publication number: 20180325946Abstract: The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.Type: ApplicationFiled: July 24, 2018Publication date: November 15, 2018Inventors: Minoru Ueda, Yoichi Yamada, Katsumi Ebisawa, Akihito Yamamoto, Kiyoshi Sakai, Kohki Matsubara, Hisashi Hattori, Masahiko Sugiyama, Takanori Inoue
-
Publication number: 20180311313Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.Type: ApplicationFiled: March 28, 2018Publication date: November 1, 2018Inventors: Akihito YAMAMOTO, Minoru UEDA, Kohki MATSUBARA, Akio SUZUMURA, Koichi FURUKAWA, Yoshihiro MATSUSHITA, Hirotaka WAKAYAMA, Nobunori TAKAHASHI, Shin TSUNEKAWA, Takako IZUMOTO
-
Patent number: 10025076Abstract: A zoom lens comprises in order from an object side, a first lens unit having a positive refractive power, a second lens unit having a negative refractive power, and a third lens unit having a positive refractive power, and the third unit having a positive refractive power comprises in order from the object side, a first lens component having a positive refractive power, and a second lens component having a negative refractive power in which, a lens having a positive refractive power and a lens having a negative refractive power are cemented, and the zoom lens satisfies the following conditional expressions (1), (2), and (3) 1.4<|f3_2p/f3_2n|<2.6??(1) nd3_2p?nd3_2n?0??(2) nd3_2n?1.8??(3).Type: GrantFiled: January 26, 2016Date of Patent: July 17, 2018Assignee: OLYMPUS CORPORATIONInventors: Tetsuya Yanai, Minoru Ueda, Mayu Miki
-
Patent number: 10018813Abstract: A zoom lens comprises in order from an object side, a first lens unit having a positive refractive power, a second lens unit having a negative refractive power, and a third lens unit having a positive refractive power, and the third unit having a positive refractive power comprises in order from the object side, a first lens component having a positive refractive power, and a second lens component having a negative refractive power in which, a lens having a positive refractive power and a lens having a negative refractive power are cemented, and the zoom lens satisfies the following conditional expressions (1), (2), and (3). 1.4<|f3_2p/f3_2n|<2.6??(1) nd3_2p?nd3_2n?0??(2) nd3_2n?1.8??(3).Type: GrantFiled: January 26, 2016Date of Patent: July 10, 2018Assignee: OLYMPUS CORPORATIONInventors: Tetsuya Yanai, Minoru Ueda, Mayu Miki
-
Patent number: 9962428Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.Type: GrantFiled: December 24, 2013Date of Patent: May 8, 2018Assignee: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITYInventors: Akihito Yamamoto, Minoru Ueda, Kohki Matsubara, Akio Suzumura, Koichi Furukawa, Yoshihiro Matsushita, Hirotaka Wakayama, Nobunori Takahashi, Shin Tsunekawa, Takako Izumoto
-
Publication number: 20170355960Abstract: The purpose of the present invention is to provide immortalized stem cells, which produce a growth factor capable of regenerating various kinds of tissues that have been damaged by a variety of causes, and a method for producing the aforesaid immortalized stem cells. Another purpose is to provide a medicinal composition and a medicinal preparation for restoring damaged tissues, and a method for the percutaneous absorption of a culture supernatant. Provided are immortalized stem cells that are obtained by isolating stem cells selected from the group consisting of mammalian mesenchymal cells, an embryo at the early stage of the development and somatic cells, first culturing the cells to give first stage culture cells, transferring four kinds of genes into the first stage culture cells to give transgenic cells, and selecting the desired immortalized stem cells from among the transgenic cells using the expression of STRO-1 as an index.Type: ApplicationFiled: June 26, 2017Publication date: December 14, 2017Inventor: Minoru Ueda
-
Publication number: 20170027201Abstract: According to a manufacturing method of the present invention, Class 2 food allergens can be decomposed even if a protease is not used, and thus a manufacturing cost is inexpensive, and a food composition having a reduced content of Class 2 food allergens can be provided without using salt water which has an effect on the taste. The fermented food composition, obtained by the manufacturing method of the present invention, has a sufficiently reduced content of the Class 2 food allergens, and thus even those who contracts pollinosis or latex allergy can safely take it. The fermented food composition is tasty, and thus it can be used instead of food having the Class 2 food allergens.Type: ApplicationFiled: March 20, 2015Publication date: February 2, 2017Inventors: Airo TATEGAKI, Minoru UEDA
-
Publication number: 20170007677Abstract: The invention provides a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27° C. under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.Type: ApplicationFiled: January 23, 2015Publication date: January 12, 2017Inventor: Minoru Ueda
-
Publication number: 20160193387Abstract: The purpose of the present invention is to provide: a method for preparing a cell product for use in the production of an implant, which can improve the surface properties of a material by a simple technique and can integrate a bone with a metallic implant material satisfactorily within a given period of time; a product produced by the method; and a sophisticated implant produced using the product. A cell product containing Col-I, OCN, OPN, BSP, fibronectin and VEGF or another growth factor which are produced by a bone marrow stromal cell or an immortalized milk teeth stem cell is prepared from the bone marrow stromal cell or the immortalized milk teeth stem cell, and a sophisticated implant having the growth factor immobilized on the surface thereof is provided using the resultant cell product and a mineralizing solution.Type: ApplicationFiled: December 26, 2013Publication date: July 7, 2016Applicant: QUARRYMEN CORPORATIONInventor: Minoru Ueda
-
Patent number: 9383558Abstract: A zoom lens comprising, a first lens unit having a positive refractive power, a second lens unit having a negative refractive power, a third lens unit having a positive refractive power, a fourth lens unit having a negative refractive power, and a fifth lens unit having a positive refractive power. Each distance between the first lens unit and the second lens unit, between the third lens unit and the fourth lens unit, and between the fourth lens unit and the fourth lens unit at the telephoto end is longer than at the wide angle end, and a distance between the second lens unit and the third lens unit at the telephoto end is shorter than at the wide angle end, and the following conditional expressions are satisfied. 2<mg3t/mg3w<6 1.2<mg5t/mg5w<4 0.02<f5/ft<0.Type: GrantFiled: August 27, 2015Date of Patent: July 5, 2016Assignee: Olympus CorporationInventors: Masaru Morooka, Toyoki Kon, Masahiro Imamura, Minoru Ueda
-
Patent number: RE47204Abstract: A zoom lens includes, in order from the object side, a first lens unit having a negative refractive power, a second lens unit having a positive refractive power, and a third lens unit having a positive refractive power. The first lens unit includes a negative lens and a positive lens. The zoom lens satisfies the following conditional expression (1): ?d13/ft<0.4??(1) where ?d13 is the total sum of the thickness of the lenses included in the first to third lens units of the zoom lens on the optical axis, and ft is the focal length of the entire zoom lens system at the telephoto end.Type: GrantFiled: March 22, 2016Date of Patent: January 15, 2019Assignee: OLYMPUS CORPORATIONInventors: Minoru Ueda, Masahito Watanabe, Masahiro Imamura, Mayu Miki